Diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has been successful thanks to its continuous glucose monitoring (CGM) devices that allow diabetes patients to check their blood glucose levels in real time.

While the growing adoption of this technology has generally bolstered its revenue, the company's top-line growth rates have dropped of late. However, DexCom's stock still performed slightly better than the broader market over the past year as several developments helped put the wind in the company's sails.

How will the next 12 months go for DexCom? And is the stock a buy right now? Let's find out.

Continue reading

Source Fool.com